The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib + rituximab versus FCR in younger Chronic Lymphocytic Leukemia (CLL) patients
Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Published: 06 December 2018
Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...
Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...
Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...
Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...
Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...
Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...
Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...
Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...
Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...
Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...
Follow @OBRTweets